SIGLEC22P

Across TCGA pan-cancer cohorts, SIGLEC22P RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of SIGLEC22P’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SIGLEC22P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SIGLEC22P is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

KIRC, LUAD, and KIRP are the cancer types where SIGLEC22P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SIGLEC22P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.621	<.001	11	view →
LUAD	Male	II,III,IV	−0.863	<.001	9	view →
KIRP	Male	All	+0.509	<.001	9	view →
LUSC	Male	All	−0.967	<.001	6	view →
HNSC	Female	All	+0.201	.005	6	view →
PAAD	All	All	−1.162	.013	2	view →
LIHC	Female	II,III,IV	+0.183	.019	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

SIGLEC22P–KIRC

Open the KIRC breakdown →